V. D. Dodge, E. M. Cox
Dodge & Cox Stock Fund
Dodge & Cox Stock Fund Portfolio 13F
Dodge & Cox Stock Fund Holdings Activity
- Portfolio value:
- $92.43B≈ (-$314M≈)
- Previous value:
- $92.75B≈
- # of changes:
- 81
- New positions:
- 4
- Reported for:
- 30 Sep 2023 (Q3)
- Latest filing date:
- 27 Nov 2023
Dodge & Cox Stock Fund has disclosed a total of 81 changes to the portfolio in the (2023 Q3) SEC report(s): increased the number of shares of 45, bought 4 totally new and decreased the number of shares of 32 position(s).
What stocks did Dodge & Cox Stock Fund buy in 2023 Q3?
During 2023 Q3 Dodge & Cox Stock Fund has bought 49 securities out of which top 5 purchases (by % change to portfolio) were (SCHW) Charles Schwab Corp (added shares +0.53%), (CI) Cigna Corp (added shares +14.17%), (MET) MetLife Inc (added shares +0.54%), (GILD) Gilead Sciences Inc (added shares +0.53%) and (GSK) GlaxoSmithKline PLC ADR (added shares +0.54%).
What did Dodge & Cox Stock Fund invest in during 2023 Q3?
In the 2023 Q3 report(s) the following changes have been made to the top investments: (OXY) Occidental Petroleum Corp (reduced shares -0.27%), (WFC) Wells Fargo & Company (reduced shares -0.73%), (SNY) Sanofi ADR (reduced shares -0.16%), (SCHW) Charles Schwab Corp (added shares +0.53%) and (GOOG) Alphabet Inc, CL-C (reduced shares -13.68%).
81 results
| History | Ticker | Name |
% or activity |
Shares change |
Shares held after* |
% change to portfolio |
Reported price* |
% difference current price* |
% of portfolio |
Held since* | Held for* |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Neurocrine Biosciences Inc
|
new
|
+142,330
|
142,330
|
+0.02%
|
$112.50
|
+48.05%($166.56)
|
0.02%
|
2023 Q3
|
≈ 0.25 years
|
|
|
|
VF Corp
|
new
|
+20,765,500
|
20,765,500
|
+0.4%
|
$17.67
|
-18.45%($14.41)
|
0.40%
|
2023 Q3
|
≈ 0.25 years
|
|
|
|
Avantor Inc
|
new
|
+5,929,600
|
5,929,600
|
+0.14%
|
$21.08
|
-35.10%($13.68)
|
0.14%
|
2023 Q3
|
≈ 0.25 years
|
|
|
|
Baxter International Inc
|
new
|
+4,583,700
|
4,583,700
|
+0.19%
|
$37.74
|
-30.60%($26.19)
|
0.19%
|
2023 Q3
|
≈ 0.25 years
|
|
|
|
Truist Financial Corp
|
+96.74%
|
+16,832,100
|
34,231,377
|
+0.52%
|
$28.61
|
+81.39%($51.90)
|
1.06%
|
2019 Q3
|
≈ 4.25 years
|
|
|
|
CVS Health Corp
|
+71.03%
|
+7,617,500
|
18,341,100
|
+0.58%
|
$69.82
|
+50.77%($105.26)
|
1.39%
|
2019 Q3
|
≈ 4.25 years
|
|
|
|
Norfolk Southern Corp
|
+62.59%
|
+1,557,145
|
4,044,900
|
+0.33%
|
$196.93
|
+70.22%($335.22)
|
0.86%
|
2023 Q2
|
≈ 0.50 years
|
|
|
|
Bank of America Corp
|
+62.45%
|
+18,109,300
|
47,109,200
|
+0.54%
|
$27.38
|
+126.90%($62.13)
|
1.40%
|
2019 Q3
|
≈ 4.25 years
|
|
|
|
Anheuser Busch Inbev NV ADR
|
+31.20%
|
+5,523,800
|
23,225,700
|
+0.33%
|
$55.30
|
+56.15%($86.35)
|
1.39%
|
2021 Q4
|
≈ 2.00 years
|
|
|
|
Fidelity National Information Services Inc
|
+24.53%
|
+4,432,300
|
22,503,100
|
+0.27%
|
$55.27
|
-19.32%($44.59)
|
1.35%
|
2022 Q2
|
≈ 1.50 years
|
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
* Current price: this can be a delayed price and may not reflect the real-time market value, however it is too close.
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* Held since / Held for: calculated since the latest "new buy" position. If the security was previously exited and re-entered, only the most recent holding period is counted.